Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.

@article{Lock2016CotargetingMA,
  title={Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.},
  author={Rebecca Lock and Rachel Ingraham and Oph{\'e}lia Maertens and Abigail L. Miller and Nelly Weledji and Eric Legius and Bruce M Konicek and Sau-chi Betty Yan and Jeremy R. Graff and Karen M. Cichowski},
  journal={The Journal of clinical investigation},
  year={2016},
  volume={126 6},
  pages={
          2181-90
        }
}
Neurofibromin 1-mutant (NF1-mutant) cancers are driven by excessive Ras signaling; however, there are currently no effective therapies for these or other Ras-dependent tumors. While combined MEK and mTORC1 suppression causes regression of NF1-deficient malignancies in animal models, the potential toxicity of cotargeting these 2 major signaling pathways in humans may necessitate the identification of more refined, cancer-specific signaling nodes. Here, we have provided evidence that MAPK… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors

Elliot Kahen, Andrew S. Brohl, +9 authors Damon R. Reed
  • Oncotarget
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Cancer as an ecomolecular disease and a neoplastic consortium.

  • Biochimica et biophysica acta. Reviews on cancer
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES